HROW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harrow Inc (HROW) is not a strong buy right now for a Beginner investor focused on the long term. The pre-market dip is small, but the stock is still technically mixed, analyst targets have been steadily cut, and there is no fresh news or financial snapshot to confirm a new acceleration phase. Since the user is impatient and not waiting for a better setup, I still would not call this a clear buy today; the better call is to hold off and wait for a stronger confirmation of trend and fundamentals.
HROW is showing short-term momentum improvement but the broader trend is still weak. MACD histogram is positive and expanding, which supports near-term upside momentum. However, the moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, indicating the longer trend has not reversed. RSI_6 at 68.458 is near overbought/upper-neutral territory, so upside from here may be limited in the very short term. Price at 35.15 is just below R1 at 35.162 and above the pivot at 32.44, so the stock is testing resistance rather than offering a deep-value entry. The next resistance is 36.844, with support at 29.719.
Analysts still broadly maintain Buy/Overweight ratings. B. Riley highlighted improving momentum in IHEEZO and Triesence, upcoming product and coding catalysts, and expanding commercial leverage. The analyst view also points to accelerating second-half growth and a longer-term path to higher revenue targets. Options sentiment is also bullish, with call-heavy positioning.
No news in the recent week means no fresh catalyst to re-rate the stock today. Multiple analysts have lowered price targets over the last few months, including B. Riley, Cantor Fitzgerald, Ladenburg, and Lake Street. The latest commentary cites weaker VEVYE pricing and revised growth expectations. The technical setup is also not fully bullish because longer-term moving averages remain bearish and the stock is trading right at resistance.
No usable financial snapshot was provided because of a data error, so the latest quarter cannot be assessed directly. From the analyst notes, the most recent quarter appears to have been pressured by weaker VEVYE pricing and revised growth expectations, while underlying volume trends and product mix remain constructive. The analyst commentary suggests this was more of a timing issue than a demand collapse, but there is not enough current quarter financial data here to justify a strong buy.
Wall Street remains positive overall, with several Buy/Overweight ratings still in place. However, the trend in price targets has been downward over the last few months: B. Riley cut to $60 from $65, Cantor Fitzgerald to $88 from $91, B. Riley earlier to $65 from $74, Ladenburg to $62 from $66, and Lake Street to $60 from $70. The pros view is that growth catalysts and leverage are building; the cons view is that near-term pricing pressure and tempered growth expectations are forcing target cuts. Overall, analysts are constructive but less enthusiastic than before.
